EP2440210A4 - Verfahren zur behandlung von magen-darm-erkrankungen - Google Patents

Verfahren zur behandlung von magen-darm-erkrankungen

Info

Publication number
EP2440210A4
EP2440210A4 EP10786942.2A EP10786942A EP2440210A4 EP 2440210 A4 EP2440210 A4 EP 2440210A4 EP 10786942 A EP10786942 A EP 10786942A EP 2440210 A4 EP2440210 A4 EP 2440210A4
Authority
EP
European Patent Office
Prior art keywords
methods
gastrointestinal disorders
treating gastrointestinal
disorders
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10786942.2A
Other languages
English (en)
French (fr)
Other versions
EP2440210A2 (de
Inventor
Elaine Phillips
Malcolm Hill
Adam Simpson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viropharma Biologics LLC
Original Assignee
Meritage Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meritage Pharma Inc filed Critical Meritage Pharma Inc
Publication of EP2440210A2 publication Critical patent/EP2440210A2/de
Publication of EP2440210A4 publication Critical patent/EP2440210A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10786942.2A 2009-06-12 2010-06-11 Verfahren zur behandlung von magen-darm-erkrankungen Withdrawn EP2440210A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18677709P 2009-06-12 2009-06-12
PCT/US2010/038411 WO2010144865A2 (en) 2009-06-12 2010-06-11 Methods for treating gastrointestinal disorders

Publications (2)

Publication Number Publication Date
EP2440210A2 EP2440210A2 (de) 2012-04-18
EP2440210A4 true EP2440210A4 (de) 2014-01-29

Family

ID=43309491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10786942.2A Withdrawn EP2440210A4 (de) 2009-06-12 2010-06-11 Verfahren zur behandlung von magen-darm-erkrankungen

Country Status (4)

Country Link
US (1) US20110097401A1 (de)
EP (1) EP2440210A4 (de)
CA (1) CA2765033C (de)
WO (1) WO2010144865A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
EP3574914B1 (de) 2007-11-13 2021-12-29 ViroPharma Biologics LLC Kortikosteroidzusammensetzungen
DK2151235T3 (da) * 2008-07-21 2011-04-11 Falk Pharma Gmbh Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
US8032081B2 (en) * 2009-03-31 2011-10-04 GM Global Technology Operations LLC Using V2X in-network session maintenance protocols to enable instant chatting applications
AU2010279575B2 (en) 2009-08-03 2016-05-05 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
ES2683864T3 (es) 2009-10-01 2018-09-28 Adare Pharmaceuticals, Inc. Composiciones de corticosteroides administradas oralmente
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
JP2013536694A (ja) * 2010-09-07 2013-09-26 カーギル インコーポレイテッド 凝固糖アルコール混合物
EP2446877A1 (de) * 2010-10-29 2012-05-02 Roquette Frères Modifizierte Matrix auf Stärkederivatbasis zur Dickdarmansteuerung
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) * 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2012087113A1 (en) 2010-12-24 2012-06-28 N.V. Nutricia Improved nutritional tablet
AU2012214224B2 (en) 2011-02-11 2016-03-17 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU2011248587A1 (en) * 2011-11-09 2013-05-23 Cosmo Technologies Ltd Controlled release and taste masking oral pharmaceutical composition
EP2844298B1 (de) * 2012-04-30 2024-01-03 Karici Diagnostics Inc., Komplex mit carboxylsubstituierter stärke und lipid zur verzögerten freisetzung von wirkstoffen
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
AU2013290141A1 (en) 2012-07-11 2015-02-05 Alvaro F. Guillem Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
WO2014025832A1 (en) * 2012-08-06 2014-02-13 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
MY174758A (en) * 2012-09-11 2020-05-13 Norgine Bv Compositions comprising peg and ascorbate
CA2891053C (en) 2012-10-22 2020-12-01 ZS Pharma, Inc. Microporous zirconium silicate for treating hyperkalemia
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
WO2014119836A1 (en) * 2013-01-30 2014-08-07 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
WO2015034678A2 (en) * 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CN106170283B (zh) * 2013-11-08 2019-08-20 Zs制药公司 用于治疗高钾血症的微孔硅酸锆
MX2016005955A (es) * 2013-11-08 2016-12-02 Zs Pharma Inc Silicato de zirconio microporoso para el tratamiento de la hiperpotasemia.
PT2886108T (pt) * 2013-12-23 2019-04-01 Dr Falk Pharma Gmbh Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago
EP2886121A1 (de) 2013-12-23 2015-06-24 Dr. Falk Pharma Gmbh Wässrige Suspension enthaltend Budesonid zur Behandlung von entzündlichen Veränderungen des Ösophagus
US10076550B2 (en) * 2014-06-25 2018-09-18 Council Of Scientific & Industrial Research Synergistic pharmaceutical composition for gastroinestinal disorders
WO2016205172A1 (en) 2015-06-15 2016-12-22 Banner Life Sciences Llc Soft lozenges comprising corticosteroids
US9867834B2 (en) 2015-06-15 2018-01-16 Banner Life Sciences Llc Non-systemic topical compositions comprising corticosteroids
BR112018001859B1 (pt) 2015-07-30 2023-05-02 Takeda Pharmaceutical Company Limited Comprimido, e, método para produzir um comprimido
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
IT201600101413A1 (it) 2016-10-10 2018-04-10 Sofar Swiss S A Composizione liquida per uso nel trattamento del reflusso gastroesofageo
CN106525838A (zh) * 2016-12-07 2017-03-22 百奥森（江苏）食品安全科技有限公司 一种泼尼松龙检测方法及检测卡
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
WO2019067680A1 (en) 2017-09-27 2019-04-04 Cook Medical Technologies Llc CROSSLINKING SUBMUCOSAL INJECTION SYSTEM
BR112022023307A2 (pt) 2020-05-18 2022-12-20 Orexo Ab Composição farmacêutica para entrega de fármacos
TW202245792A (zh) * 2021-01-22 2022-12-01 美商風樹療法公司 靜脈注射伊司他星用於治療急性心臟衰竭
EP4236921A1 (de) 2021-11-25 2023-09-06 Orexo AB Adrenalin enthaltende pharmazeutische zusammensetzung
US20230277464A1 (en) * 2022-03-04 2023-09-07 Abitec Corporation Tablet dosage forms for lipid-based drug delivery systems
US20230292992A1 (en) * 2022-03-18 2023-09-21 CapsoVision, Inc. Apparatus for Thermally Stable Capsule Endoscope Using Effervescent Formulation for Controlling Balloon Inflation Rate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
US20070111978A1 (en) * 2005-11-12 2007-05-17 Ranjan Dohil Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2008061160A1 (en) * 2006-11-14 2008-05-22 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
WO2009064417A2 (en) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
WO2011041509A1 (en) * 2009-10-01 2011-04-07 Eurand, Inc. Orally administered corticosteroid compositions

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
GB8628359D0 (en) 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5215752A (en) 1988-03-17 1993-06-01 Vectorpharma International S.P.A. Pharmaceutical tablets and capsule granulates of scleroglucan and active substance
US4900552A (en) * 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5244668A (en) 1988-10-14 1993-09-14 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
DK0587744T3 (da) 1991-05-28 2003-10-20 Mcneil Ppc Inc Tygbar sammensætning til frigørelse af et lægemiddel
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
EP0627218B1 (de) 1992-02-18 2001-12-19 Nippon Shinyaku Company, Limited Verfahren zur Herstellung von schnelllöslicher Tabletten und schnelllöslichen Tablette beinhaltend Xylitol
WO1993017663A1 (en) * 1992-03-10 1993-09-16 Fisons Plc Pharmaceutical inhalation compositions
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
IL108366A (en) 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5993860A (en) 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US6020002A (en) 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5711936A (en) * 1995-06-05 1998-01-27 Whitehill Oral Technologies, Inc. Ultramulsion based ingestible compositions
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
RU2189227C2 (ru) 1996-07-12 2002-09-20 Дайити Фармасьютикал Ко., Лтд. Быстро распадающиеся прессованные в формах материалы и способ их получения
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6071539A (en) 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
NZ334914A (en) 1996-10-01 2000-09-29 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
US5709866A (en) 1996-12-05 1998-01-20 Sage Products, Inc. Dual bag mouth care package
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6080427A (en) 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
US5976577A (en) 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
JP2001517493A (ja) * 1997-09-26 2001-10-09 ノーヴェン ファーマシューティカルズ インコーポレイテッド 生体接着剤組成物及び活性薬剤の局所投与方法
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
IL137734A0 (en) * 1998-02-11 2001-10-31 Res Triangle Pharm Ltd Method and composition for treatment of inflammatory conditions
AU741992B2 (en) 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
DE19809719A1 (de) 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
AU742009B2 (en) 1998-04-09 2001-12-13 Adare Pharmaceuticals S.R.L. Wettable microcapsules having hydrophobic polymer coated cores
EP0955040A1 (de) 1998-04-27 1999-11-10 ASTA Medica Aktiengesellschaft Arzneiform zur oralen Applikation von Mesna
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
ES2274625T3 (es) 1998-05-18 2007-05-16 Takeda Pharmaceutical Company Limited Comprimidos desintegrables en la boca que comprenden un bencimidazol.
US6071523A (en) 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
GB9812426D0 (en) * 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6028095A (en) * 1998-10-15 2000-02-22 Warner-Lambert Company Treatment of inflammatory bowel disease using histamine H3 -receptor agonists
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6635281B2 (en) * 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20020071864A1 (en) 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6426090B1 (en) 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
US6162466A (en) 1999-04-15 2000-12-19 Taro Pharmaceutical Industries Ltd. Sustained release formulation of carbamazepine
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
ATE251449T1 (de) 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US6350480B1 (en) 1999-12-30 2002-02-26 Wm. Wrigley Jr. Company Chewing gum product including a hydrophilic gum base and method of producing
WO2001063633A1 (en) * 2000-02-22 2001-08-30 U S Army Inst Of Surgical Res Syringe holder attachment for attaching a syringe to a medication bottle
IT1318404B1 (it) 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6656492B2 (en) 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
AU2001294192A1 (en) 2000-10-06 2002-04-22 Takeda Chemical Industries Ltd. Solid preparations
RU2273472C2 (ru) * 2000-10-16 2006-04-10 Дайити Фармасьютикал Ко., Лтд. Лекарственный состав, быстро распадающийся в ротовой полости, и способ его изготовления
EP1330250B1 (de) 2000-10-30 2004-05-12 Lupin Limited Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
SI1341528T1 (sl) 2000-12-07 2012-05-31 Nycomed Gmbh Hitro razpadljiva tableta ki obsega kislinsko labilno aktivno sestavino
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US20020122823A1 (en) 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
DE60236850D1 (de) 2001-02-15 2010-08-12 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
KR20030094272A (ko) 2001-03-06 2003-12-11 교와 핫꼬 고교 가부시끼가이샤 구강내 급속 붕괴성 정제
ATE477804T1 (de) * 2001-03-15 2010-09-15 Soligenix Inc Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
ATE345112T1 (de) 2001-05-11 2006-12-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US6613346B2 (en) 2001-06-28 2003-09-02 Wm. Wrigley, Jr. Company Chewable product including active ingredient
US6602518B2 (en) 2001-06-28 2003-08-05 Wm. Wrigley Jr. Company Chewable product including active ingredient
DE60219478T2 (de) 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
AP2004002999A0 (en) 2001-09-26 2004-03-31 Pharmacia Corp Organoleptically acceptable intraorally disintegrating compositions
US20030235618A1 (en) 2001-10-22 2003-12-25 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
EP1438026B1 (de) 2001-10-22 2011-04-13 Taro Pharmaceutical Industries Limited Den geschmack verdeckende auslaufsichere formulierung
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
TWI332400B (en) 2001-12-14 2010-11-01 Solvay Pharm Gmbh Preformulation for the tableting of natural mixtures of conjugated estrogens
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
AU2002366796A1 (en) * 2001-12-19 2003-07-09 Eisai Co. Ltd Methods using proton pump inhibitors
US7887838B2 (en) 2002-01-18 2011-02-15 Banner Pharmacaps, Inc. Non-gelatin film and method and apparatus for producing same
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2003074085A1 (fr) 2002-03-06 2003-09-12 Kyowa Hakko Kogyo Co., Ltd. Comprimes a desintegration rapide dans la cavite buccale
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
AU2003238670A1 (en) 2002-04-05 2003-10-27 Cadila Healthcare Limited Fast disintegrating oral dosage forms
CA2482746A1 (en) 2002-04-19 2003-11-27 Astion Development A/S Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
ES2199061B1 (es) 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
ATE541562T1 (de) 2002-06-17 2012-02-15 Taro Pharmaceuticals Usa Inc Ibuprofen-suspension
US20040001885A1 (en) 2002-06-27 2004-01-01 Unchalee Kositprapa Rapidly disintegrating antihistamine formulation
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
JP4137551B2 (ja) * 2002-08-09 2008-08-20 日東電工株式会社 透明導電性基板用表面保護フィルム及び表面保護フィルム付き透明導電性基板
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
AU2003291314B2 (en) * 2002-11-05 2007-07-26 Corcept Therapeutics, Inc. Methods for treating migraine
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004062692A1 (en) 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
EP1595533B1 (de) 2003-01-21 2010-01-06 Nippon Shinyaku Co., Ltd. Rasch in der mundhöhle schmelzende tablette
EP1594470A4 (de) 2003-02-19 2007-10-17 Biovail Lab Int Srl Schnell absorbierende selektive 5-ht-agonisten-formulierungen
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US7749533B2 (en) 2003-05-07 2010-07-06 Akina, Inc. Highly plastic granules for making fast melting tablets
US7758497B2 (en) * 2003-06-20 2010-07-20 Contura A/S Endoscopic attachment device
US20040265372A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
EP1709975A1 (de) 2003-07-10 2006-10-11 Kyowa Hakko Kogyo Co., Ltd. Tablette und herstellungsverfahren dafür
US20050074489A1 (en) * 2003-10-01 2005-04-07 Pediamed Pharmaceuticals, Inc. Effervescent and effervescent-dispersion compositions for medicaments and methods of use thereof
EP1674083B1 (de) 2003-10-15 2018-08-01 Fuji Chemical Industry Co., Ltd. Tablette mit schneller auflösung in der mundhöhle
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US20050095271A1 (en) * 2003-10-23 2005-05-05 Crank Sports, Inc. Electrolyte Energy Gel
US20050175689A1 (en) 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US7758877B2 (en) 2004-02-05 2010-07-20 Taro Pharmaceuticals U.S.A., Inc. Stable loratadine spill resistant formulation
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US20070196474A1 (en) 2004-04-30 2007-08-23 Withiam Michael C Rapidly disintegrating low friability tablets comprising calcium carbonate
US20070196477A1 (en) 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area calcium phosphates
US20070196476A1 (en) 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area titanium dioxide
US20050244493A1 (en) 2004-04-30 2005-11-03 Withiam Michael C Rapidly disintegrating tablets comprising calcium carbonate
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
AU2005256653B2 (en) 2004-06-28 2010-10-14 Solvay Pharmaceuticals B.V. Oral sustained release formulation of tedisamil with gastric retention properties
JP2008506668A (ja) 2004-07-15 2008-03-06 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ３−アミノ−８−（１−ピペラジニル）−２ｈ−１−ベンゾピラン−２−オンの長時間放出型調製物
US20060013874A1 (en) * 2004-07-15 2006-01-19 Solvay Pharmaceuticals B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8758814B2 (en) * 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US20080008762A1 (en) * 2004-11-17 2008-01-10 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Steroid Formulation And Methods Of Treatment Using Same
TW200633713A (en) 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
AU2006244112B2 (en) 2005-05-06 2011-02-17 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
WO2007008576A2 (en) 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
ES2320174T3 (es) 2005-08-15 2009-05-19 Solvay Pharmaceuticals Gmbh Microesferas de pancreatina adecuadas para el revestimiento enterico.
UA92030C2 (ru) 2005-08-15 2010-09-27 Солвей Фармасьютикалс Гмбх Фармацевтические композиции регулированного высвобождения нестабильных в кислой среде лекарственных средств
CN103948609A (zh) 2005-08-24 2014-07-30 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20070092559A1 (en) 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
JP2009514890A (ja) 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
JP2009519334A (ja) 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
JP5331487B2 (ja) 2006-03-09 2013-10-30 サリックス ファーマシューティカルズ， インコーポレイテッド リファキシム抗直腸機能不全製剤
MX2008012299A (es) 2006-03-31 2008-11-18 Rubicon Res Private Ltd Tabletas de desintegracion oral.
WO2007117605A2 (en) 2006-04-06 2007-10-18 Taro Pharmaceuticals North America, Inc. Novel spill-resistant formulations comprising hydrocolloidal polymers
US20070292508A1 (en) 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
EP1870102A1 (de) 2006-06-15 2007-12-26 Alpex Pharma SA Meloxicam enthaltende feste Formen mit verbessertem Geschmack und Verfahren zu ihrer Herstellung
US7454596B2 (en) * 2006-06-29 2008-11-18 Intel Corporation Method and apparatus for partitioned pipelined fetching of multiple execution threads
US20080008743A1 (en) 2006-07-06 2008-01-10 Forest Laboratories Holdings Limited Orally Dissolving Formulations of Memantine
BRPI0714724A8 (pt) 2006-08-02 2018-04-10 Salix Pharmaceuticals Inc métodos para tratar enterite, para proteger contra a enterite, contra a lesão à mucosa do cólon e contra a inflamação colorretal induzidas pela radiação, para tratar enterite em um indivíduo ou monitorar o progresso de um indivíduo que é tratado de enterite, para selecionar um indivíduo para o tratamento de enterite, e, para tratar diarréia profilaticamente.
WO2008039472A2 (en) 2006-09-26 2008-04-03 Taro Pharmaceuticals North America, Inc. Stabilizing compositions for antibiotics and methods of use
AU2007304425B2 (en) 2006-10-02 2013-12-05 Spepharma Ag Non-mucoadhesive film dosage forms
US7536990B2 (en) * 2006-11-21 2009-05-26 Emcon Technologies Llc Hybrid exhaust valve assembly
WO2008070129A2 (en) 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2008079342A2 (en) 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
EP2101739A2 (de) 2006-12-21 2009-09-23 Mallinckrodt Inc. Zusammensetzung und verfahren zur herstellung von im mund zerfallenden tabletten mit einer hohen wirkstoffdosis
AU2008215771A1 (en) 2007-02-15 2008-08-21 Derma-Young Ltd. Compositions and methods for enhancing transmucosal delivery
CA2617688C (en) 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
EP2044929A1 (de) 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Schnell lösliche Tabletten für orale Anwendung
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
WO2009076361A1 (en) 2007-12-10 2009-06-18 Eurand, Inc. Orally disintegrating tablets comprising diphenhydramine
KR20100103844A (ko) 2007-12-21 2010-09-28 유란드, 인코포레이티드 테마제팜의 경구 붕해 타블릿 조성물
WO2009102830A1 (en) 2008-02-13 2009-08-20 Eurand Inc Orally disintegrating tablet compositions of ranitidine and methods of manufacture
DK2151235T3 (da) 2008-07-21 2011-04-11 Falk Pharma Gmbh Farmaceutisk formulering til behandling af den øvre fordøjelseskanal

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
US20070111978A1 (en) * 2005-11-12 2007-05-17 Ranjan Dohil Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2008061160A1 (en) * 2006-11-14 2008-05-22 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
WO2009064417A2 (en) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
WO2011041509A1 (en) * 2009-10-01 2011-04-07 Eurand, Inc. Orally administered corticosteroid compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010144865A2 *

Also Published As

Publication number Publication date
WO2010144865A9 (en) 2011-08-18
US20110097401A1 (en) 2011-04-28
EP2440210A2 (de) 2012-04-18
CA2765033A1 (en) 2010-12-16
WO2010144865A2 (en) 2010-12-16
CA2765033C (en) 2020-07-14

Similar Documents

Publication Publication Date Title
EP2440210A4 (de) Verfahren zur behandlung von magen-darm-erkrankungen
IL253038A0 (en) Preparations and methods for the treatment or prevention of infections. my voice
MX2011007930A (es) Conjugados de insulina cristalina.
WO2009064819A3 (en) Compositions for the treatment of gastrointestinal inflammation
IL291460A (en) Bacterial strains, their compositions and their use in the treatment of gastrointestinal disorders
MX350046B (es) Tratamientos para trastornos gastrointestinales.
WO2012048099A3 (en) Nanoparticle-loaded cells
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
IL291445A (en) Bacterial strains, their compositions and their use in the treatment of gastrointestinal disorders
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
GEP20156226B (en) Compositions for treating centrally mediated nausea and vomiting
EP2328417A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von beta-amyloid-vermittelten erkrankungen und synukleinopathien
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
EP2480226A4 (de) Zusammensetzung mit s-allyl-l-cystein als wirkstoff zur verhinderung oder behandlung von magen-darm-erkrankungen
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
EP2490721A4 (de) Zusammensetzungen, behandlungsverfahren und diagnose autoimmun-vermittelter erkrankungen sowie verfahren zur herstellung solcher zusammensetzungen
WO2011008947A3 (en) Treatment and diagnosis of immune disorders
WO2010129347A3 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
WO2011029639A3 (en) Compounds and methods for treating neoplasia
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2009126695A3 (en) Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
WO2008103431A3 (en) Dnai - liposomes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120109

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140108

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/16 20060101ALI20131220BHEP

Ipc: A61P 1/04 20060101ALI20131220BHEP

Ipc: A61K 9/00 20060101ALI20131220BHEP

Ipc: A61K 9/20 20060101ALI20131220BHEP

Ipc: A61K 31/56 20060101AFI20131220BHEP

Ipc: A61P 1/00 20060101ALI20131220BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VIROPHARMA BIOLOGICS LLC

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/04 20060101ALI20211208BHEP

Ipc: A61P 1/00 20060101ALI20211208BHEP

Ipc: A61K 31/56 20060101ALI20211208BHEP

Ipc: A61K 9/00 20060101AFI20211208BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220614